MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Funding Opportunities: Pioneers, Architects & Consolidators
Funding: Strategic Corporate Investment & Corporate Venture Capital (CVC)
Portfolio Companies: Merck Alliance
GlycoFi
Parents
*Architects: Biotechnology _Monoclonal, Polyclonal, Bispecific Antibodies & Antibody-Drug Conjugates (ADC)s
*Architects: Biotechnology_ Glycomics - Sugars
*Portfolio Companies: Boston Millenia
*Portfolio Companies: Polaris Venture
*Portfolio Companies: SVLS (SV Life Sciences)
*Portfolio Companies: Village Ventures
Companies: Acquired_(M&A)
Finance & Acquisitions: Merck & Co.
Industry: New Hampshire
Portfolio Companies: Merck Alliance
Children
$400 million Merck acquisition (2006)
Can dramatically improve the pharmaceutical attributes of a drug
CEO: Tillman Gerngross, Adimab, Director, Arsanis
Increase the effector function of monoclonal antibodies through selection of specific glycan structures which increase binding t
Increase the serum half-life of therapeutic proteins
Lebanon, New Hampshire
Protein expression technology allows optimization of exact sugar (glycan) structure of a given therapeutic protein
Targeting proteins to specific tissues to enhance their bioavailability
Jumps
Adimab
Arsanis Pharmaceuticals (ASNS)
Dr Mark Israel, MD, Director, Norris Cancer Center
GlycoMimetics, Inc. (NASDAQ: GLYC)*
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA)
Quickpath Technologies, Inc
The MITRE Corporation